1. Home
  2. CELC vs WING Comparison

CELC vs WING Comparison

Compare CELC & WING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$53.29

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Wingstop Inc.

WING

Wingstop Inc.

N/A

Current Price

$151.46

Market Cap

4.1B

ML Signal

N/A

Company Overview

Basic Information
Metric
CELC
WING
Founded
2011
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.1B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
CELC
WING
Price
$53.29
$151.46
Analyst Decision
Strong Buy
Buy
Analyst Count
13
27
Target Price
$150.85
★ $184.92
AVG Volume (30 Days)
920.9K
★ 1.4M
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
★ 0.87%
EPS Growth
N/A
★ 67.84
EPS
N/A
★ 3.30
Revenue
N/A
★ $696,853,000.00
Revenue This Year
N/A
$7.16
Revenue Next Year
$1,921.71
$14.63
P/E Ratio
★ N/A
$45.84
Revenue Growth
N/A
★ 11.35
52 Week Low
$53.54
$95.82
52 Week High
$151.02
$302.80

Technical Indicators

Market Signals
Indicator
CELC
WING
Relative Strength Index (RSI) 30.06 53.54
Support Level N/A $139.01
Resistance Level $72.76 $177.19
Average True Range (ATR) 4.24 8.94
MACD -1.03 -2.72
Stochastic Oscillator 0.16 23.41

Price Performance

Historical Comparison
CELC
WING

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

About WING Wingstop Inc.

Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across over 10 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 stores, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.

Share on Social Networks: